Conversion of cysteine to serine residues alters the activity, stability, and heparin dependence of acidic fibroblast growth factor
- PMID: 1706340
Conversion of cysteine to serine residues alters the activity, stability, and heparin dependence of acidic fibroblast growth factor
Abstract
Acidic fibroblast growth factor (aFGF) is a broad spectrum mitogen that is stabilized by complexation with heparin and heparan proteoglycans. The monomeric human protein contains 3 reduced cysteine residues of unknown function, the first 2 of which are conserved among all seven known fibroblast growth factors. The influence of these free sulfhydryl groups on the level, stability, and heparin dependence of the mitogenic activity at physiological temperature and pH is characterized using a complete set of site-directed mutants in which either any 1, 2, or all 3 of the cysteine residues are converted to serines. Mutants of aFGF in which either any 2 or all 3 cysteine residues are substituted by serines are more active, have longer activity half-lives, and are less heparin dependent than wild-type aFGF. In contrast, wild-type aFGF and the three mutants that each retain 2 cysteine residues inactivate more rapidly in the absence of heparin by a nonproteolytic mechanism but are markedly stabilized by heparin. This cysteine-mediated destabilization of aFGF not only diminishes its activity in the absence of heparin in tissue culture but also could functionally restrict its activity in vivo to the vicinity of mast cell-derived heparins and heparan proteoglycans associated with cell surfaces and basement membranes.
Similar articles
-
Disulfide bonds are neither required, present, nor compatible with full activity of human recombinant acidic fibroblast growth factor.Growth Factors. 1990;3(4):287-98. doi: 10.3109/08977199009003671. Growth Factors. 1990. PMID: 1701652
-
Thermodynamic characterization of mutants of human fibroblast growth factor 1 with an increased physiological half-life.Biochemistry. 2000 Jun 20;39(24):7153-8. doi: 10.1021/bi9927742. Biochemistry. 2000. PMID: 10852713
-
Characterization of [125I]acidic fibroblast growth factor binding to the cloned human fibroblast growth factor receptor, FGF-flg, on NIH 3T3 cell membranes: inhibitory effects of heparin, pertussis toxin and guanine nucleotides.J Pharmacol Exp Ther. 1992 Oct;263(1):253-63. J Pharmacol Exp Ther. 1992. PMID: 1383494
-
Stabilization by heparin of acidic fibroblast growth factor mitogenicity for human endothelial cells in vitro.J Cell Physiol. 1989 Sep;140(3):439-48. doi: 10.1002/jcp.1041400306. J Cell Physiol. 1989. PMID: 2777882
-
Formulation design of acidic fibroblast growth factor.Pharm Res. 1993 May;10(5):649-59. doi: 10.1023/a:1018939228201. Pharm Res. 1993. PMID: 7686672
Cited by
-
Acidic fibroblast growth factor: evaluation of topical formulations in a diabetic mouse wound healing model.Pharm Res. 1994 Jan;11(1):65-71. doi: 10.1023/a:1018993610801. Pharm Res. 1994. PMID: 7511240
-
The FGF family: biology, pathophysiology and therapy.Nat Rev Drug Discov. 2009 Mar;8(3):235-53. doi: 10.1038/nrd2792. Nat Rev Drug Discov. 2009. PMID: 19247306 Free PMC article. Review.
-
Variable expressivity of FGF3 mutations associated with deafness and LAMM syndrome.BMC Med Genet. 2011 Feb 9;12:21. doi: 10.1186/1471-2350-12-21. BMC Med Genet. 2011. PMID: 21306635 Free PMC article.
-
An Engineered Human Fibroblast Growth Factor-1 Derivative, TTHX1114, Ameliorates Short-term Corneal Nitrogen Mustard Injury in Rabbit Organ Cultures.Invest Ophthalmol Vis Sci. 2018 Sep 4;59(11):4720-4730. doi: 10.1167/iovs.18-24568. Invest Ophthalmol Vis Sci. 2018. PMID: 30267094 Free PMC article.
-
Engineering a Cysteine-Free Form of Human Fibroblast Growth Factor-1 for "Second Generation" Therapeutic Application.J Pharm Sci. 2016 Apr;105(4):1444-53. doi: 10.1016/j.xphs.2016.02.010. J Pharm Sci. 2016. PMID: 27019961 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical